Hepatitis C Virus Seroprevalence in Persons Who Inject Drugs in Korea, 2012–2022: A Multicenter, Retrospective Study-Reference-Cited by-同舟云学术

Hepatitis C Virus Seroprevalence in Persons Who Inject Drugs in Korea, 2012–2022: A Multicenter, Retrospective Study

Published:2023 Issue:48 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Kim Jihye¹^ORCID,Choi Gwang Hyeon¹^ORCID,Jang Og-Jin²³^ORCID,Chon Younghoon⁴^ORCID,Cho Sung Nam⁵^ORCID,Kwon Dohoon⁶^ORCID,Jeong Sook-Hyang¹^ORCID

Affiliation:

1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

2. Department of Psychiatry, Bugok National Hospital, Changnyeong, Korea.

3. Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.

4. Department of Psychiatry, Incheon Chamsarang Hospital, Incheon, Korea.

5. Department of Psychiatry, National Forensic Hospital, Gongju, Korea.

6. Department of Psychiatry, Daedong Hospital, Daegu, Korea.

Funder

National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2023.38.e357

Reference20 articles.

1. Epidemiology and natural history of HCV infection

2. World Health Organization. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Updated 2016. Accessed April 6, 2023. https://apps.who.int/iris/handle/10665/206453

3. World Health Organization. Interim guidance for country validation of viral hepatitis elimination. Updated 2021. Accessed April 6, 2023. https://apps.who.int/iris/handle/10665/341652

4. Prevalence and associated clinical characteristics of hepatitis B, C, and HIV infections among injecting drug users in Korea